Acusensus Completes AU$30.0 Million Placement to Support Expansion.
Acusensus Limited (ASX: ACE) has successfully secured firm commitments for an AU$30.0 million equity placement through the issue of 20.0 million new fully paid ordinary shares at AU$1.50 per share to existing and new professional and sophisticated investors. The placement attracted strong demand, broadening the shareholder base, strengthening institutional ownership, and improving free float and liquidity in Acusensus shares.
The offer price reflects a reasonable discount to recent market prices and VWAP levels, supporting efficient capital raising while maintaining investor confidence. Proceeds from the placement will be used to fund business development, contract mobilisation, acquisition of fixed assets, ongoing product innovation, working capital requirements, litigation-related expenses, and placement costs.
The capital raise positions Acusensus to accelerate its growth strategy and pursue a wider range of global opportunities in AI-enabled road safety solutions. The new shares will rank equally with existing shares and are expected to commence trading later in December 2025.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Acusensus Completes AU$30.0 Million Placement to Support Expansion.
Acusensus Limited (ASX: ACE) has successfully secured firm commitments for an AU$30.0 million equity placement through the issue of 20.0 million new fully paid ordinary shares at AU$1.50 per share to existing and new professional and sophisticated investors. The placement attracted strong demand, broadening the shareholder base, strengthening institutional ownership, and improving free float and liquidity in Acusensus shares.
The offer price reflects a reasonable discount to recent market prices and VWAP levels, supporting efficient capital raising while maintaining investor confidence. Proceeds from the placement will be used to fund business development, contract mobilisation, acquisition of fixed assets, ongoing product innovation, working capital requirements, litigation-related expenses, and placement costs.
The capital raise positions Acusensus to accelerate its growth strategy and pursue a wider range of global opportunities in AI-enabled road safety solutions. The new shares will rank equally with existing shares and are expected to commence trading later in December 2025.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au